Tempus xT Hematologic Malignancies DNA Sequencing

Tempus xR Whole Transcriptome RNA Sequencing

xT Heme + xR is a comprehensive assessment of DNA (648 genes) and RNA whole transcriptome sequencing, respectively, offering validated fusion detection*, prognostic and/or diagnostic considerations, and therapeutic matching for hematologic malignancies.

INFORMED DIAGNOSIS AND ACTIONABLE TREATMENT STRATEGIES

Current clinical guidelines recommend comprehensive genomic profiling in select hematologic malignancies to help inform diagnosis and risk stratification.1–4

Our reports include actionable information based on clinical and molecular findings, incorporating evidence from the MSK OncoKB database and NCCN GuidelinesⓇ5 , to provide therapeutic match options.

POTENTIAL USES FOR xT HEME + xR

Myelodysplastic Syndromes (MDS)

xT Heme + xR can aid in diagnosis, provide information on clonality in uncertain cases, and assess prognosis using IPSS-M1.6

Acute Leukemias

xT Heme + xR can help inform subclassification and prognosis, guide treatment decisions and risk stratify patients based on molecular findings.7

Myeloproliferative Neoplasms (MPN)

xT Heme + xR can help inform a definitive diagnosis and identify certain mutations that have prognostic significance.8

Multiple Myeloma

xT Heme + xR may help inform risk categorization that may be of prognostic and/or therapeutic value.9,10

TURNAROUND TIME

10 days from specimen receipt

Ordering Flexibility

Tempus offers a variety of options to customize molecular profiling for patients.

  • xT Heme and xR may be ordered as a standalone test or in combination
  • Streamlined ordering process through Tempus Hub, paper requisition, or directly from your EHR
Access Tempus Hub
image description

Documents

view all documents
  • UPCOMING WEBINAR:

    Specimen Guidelines

    View
Financial Assistance

We help provide access to our tests for all patients in financial need

Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission. 

  • Step 1

    Apply for financial assistance online at access.tempus.com.

  • Step 2

    If approved, you will know immediately about the maximum out-of-pocket cost of your testing.

  • Step 3

    Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

    All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.

  1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.1.2023 © National Comprehensive Cancer Network, Inc. 2022.
  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2022 © National Comprehensive Cancer Network, Inc. 2022.
  3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2022 © National Comprehensive Cancer Network, Inc. 2022.
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2023 © National Comprehensive Cancer Network, Inc. 2022.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). ©National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [6.2.23].
  6. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence. 2022;1(7). doi:https://doi.org/10.1056/evidoa2200008
  7. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med.  2016;374(23):2209-2221. doi:https://doi.org/10.1056/NEJMoa1516192
  8. Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms.N Engl J Med. 2018;379(15):1416-1430. doi:https://doi.org/10.1056/nejmoa1716614
  9. Auclair D, Anderson KC, Avigan D, Bianchi G, Biran N, Chaudhry M, Cho HJ, et al. The Myeloma-Developing Regimens Using Genomics (Mydrug) Master Protocol. J Clin Oncol. 2019;37(15_suppl):TPS8057. doi:10.1200/jco.2019.37.15_suppl.tps8057.
  10. Hu Y, Chen W, Wang J. Progress in the Identification of Gene Mutations Involved in Multiple Myeloma. OncoTargets Ther. 2019;12:4243-4253. doi:10.2147/OTT.S202243. PMID: 31213829.

*Validated fusion detection encompasses the analysis of whole transcriptome RNA seq data and/or the examination of 22 specific genes through DNA seq.

This is data-driven precision medicine

This is the future of healthcare.